



SAGE THERAPEUTICS, INC.

Science and Technology Committee Charter

A. General Statement of Purpose

The purpose of the Science and Technology Committee (the “Committee”) of the Board of Directors (the “Board”) of Sage Therapeutics, Inc. (the “Company”) is to assist the Board’s oversight of the Company’s research and development activities.

B. Committee Composition

1. Number. The Committee shall consist of such number of directors as the Board shall from time to time determine.
2. Chair. Unless the Board elects a Chair of the Committee, the Committee shall elect a Chair by majority vote.
3. Compensation. The compensation of Committee members shall be as determined by the Board.
4. Selection and Removal. Members of the Committee shall be appointed by the Board, upon the recommendation of the Nominating and Corporate Governance Committee. The Board may remove members of the Committee from such Committee, with or without cause.

C. Authority and Responsibilities

1. General. The Committee shall discharge its responsibilities, and shall assess the information provided by the Company’s management, in accordance with its business judgment.
2. Science and Technology Matters. The Committee’s responsibilities shall include:
 - a. Regularly reviewing the Company’s research and development (R&D) pipeline.
 - b. Discussing with the Company’s R&D teams the long-term strategic goals, objectives, quality and direction of the Company’s R&D programs, and providing input to the teams as they prepare their plans for further review and approval by the Board. Advising the Board regarding the Company’s long-term strategic R&D goals and objectives and the quality and direction of the Company’s R&D programs.
 - c. Discussing and evaluating new and emerging trends in pharmaceutical science, technology and regulation, and advising the Board in discussions regarding emerging technologies for building the company’s technological strength.
 - d. Advising management on approaches to acquiring and maintaining scientific technology positions; advising the Board and management on the scientific aspects of business development transactions.
 - e. Assisting the Board with its oversight responsibility for enterprise risk management in areas affecting the Company’s research and development.



- f. Discussing with the Company topics relevant to the Board's assessment of strategic R&D issues, and advising on which topics should be presented to the full Board, including among potential topics:
 - i. the quality, direction and competitiveness of the Company's R&D programs and pipeline; and
 - ii. the Company's overall intellectual property strategies.
- g. Serving as a forum to engage with the Company's R&D teams in focused discussions on other research, development and technology topics.
- h. Reviewing such other topics as delegated to the Committee from time to time by the Board.

D. Procedures and Administration

1. Meetings. The Committee shall meet from time to time as it deems necessary in order to perform its responsibilities. Such meetings may be held by video conference, telephonically or in person as the Committee deems appropriate. The Committee may also act by unanimous written consent in lieu of a meeting.
2. Minutes. The Committee shall keep minutes of its meetings in a form that it shall deem appropriate and report the same to the Board upon request.
3. Subcommittees. The Committee may form and delegate authority to one or more subcommittees (including a subcommittee consisting of a single member), as it deems appropriate from time to time under the circumstances.
4. Charter. The Committee shall, from time to time as it deems appropriate, review and reassess the adequacy of this Charter and recommend any proposed changes to the Board for approval.
5. Independent Advisors. The Committee shall have the authority to engage such external advisors as it deems necessary or appropriate to carry out its responsibilities.
6. Company Participation. The Committee may from time to time request any officer, employee or advisor of the Company to meet with the Committee or any advisors engaged by the Committee.
7. Periodic Self-Evaluation. The Committee shall periodically evaluate its own performance.

Adopted: December 16, 2022